Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Westlake Village,
Total Funding:$358.5M
Industry:Biotech
Founded:2016
Lead Investor(s):N/A

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)'s estimated annual revenue is currently $11.2M per year.(?)
  • Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)'s estimated revenue per employee is $155,000
  • Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)'s total funding is $358.5M.

Employee Data

  • Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has 72 Employees.(?)
  • Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) grew their employee count by 64% last year.
  • Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) currently has 1 job openings.

Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in medical dermatology. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our teamᅢᄁ¬ツᆲ¬トᄁs unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches. Arcutis' combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.

keywords:N/A